Skip to main content

Table 1 Subjects' anthropometric and laboratory characteristics at baseline and after 26 weeks of treatment.

From: Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

  Pioglitazone   Insulin glargine   Δ pioglitazone vs. Δ insulin glargine
P
Week 0 Week 26 P Week 0 Week 26 P  
  15   15   
Men/women 11/4   9/6   
Age(years) 60.8 ± 7.1   61.5 ± 8.2   
Diabetes Duration (years) 11.1 ± 6   9.5 ± 7.5   
BMI (kg/m2) 30.8 ± 5.5 31.9 ± 5.9 0.001 31.6 ± 6.1 32.5 ± 6.2 0.01 0.37
HbA1c (%) 8.1 ± 1.5 6.8 ± 1.2 0.001 8.3 ± 1.4 6.1 ± 0.7 0.001 0.23
Haemoglobin (g/l) 137.5 ± 11.4 127 ± 12.0 0.001 137.1 ± 10.2 132 ± 12.0 0.02 0.13
Cholesterol (mmol/l) 4.4 ± 0.9 4.2 ± 0.7 0.17 4.3 ± 1.0 4.1 ± 1.0 0.32 0.65
HDL (mmol/l) 1.1 ± 0.2 1.3 ± 0.3 0.01 1.1 ± 0.4 1.1 ± 0.4 0.49 0.01
LDL (mmol/l) 2.4 ± 0.9 2.3 ± 0.5 0.64 2.3 ± 0.7 2.4 ± 0.7 0.46 0.48
TG (mmol/l) 1.8 ± 0.8 1.5 ± 1.0 0.002 1.9 ± 1.3 1.5 ± 1.0 0.009 0.43
ALT (μcat/l) 0.7 ± 0.7 0.4 ± 0.3 0.04 0.5 ± 0.2 0.5 ± 0.2 0.12 0.87
Systolic blood pressure 142 ± 16 134 ± 10 0.04 146 ± 17 132 ± 13 0.02 0.39
Diastolic blood pressure 84 ± 8 77 ± 7 0.02 81 ± 8 73 ± 8 0.007 0.57
BNP (pmol/l) 6.9 ± 5.2 14.1 ± 16.7 0.10 9.7 ± 12.9 9.7 ± 11.6 0.41 0.51
NT-proBNP (ng/l) 11.4 ± 19.6 22.8 ± 44.0 0.046 13.6 ± 20.0 10.1 ± 9.5 0.97 0.23
  1. Values are mean ± SD. There were no significant differences between subjects' characteristics at start or after 26 weeks of treatment.